RIA Advisory Group’s AbbVie ABBV Stock Holding History

RIA Advisory Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-3,077	Closed	-$547K	–	139
2024 Q4	$547K	Buy	3,077 +146	+5%	+$26.8K	0.19%	69
2024 Q3	$579K	Buy	+2,931	New	+$547K	0.2%	59
2024 Q1	$364K	Buy	+2,002	New	+$345K	0.15%	85

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

RIA Advisory Group's ABBV Position: Q1 2025 in Review

RIA Advisory Group sold out of AbbVie (ABBV) in Q1 2025, closing a stake of 3,077 shares — an estimated $547K sold.

RIA Advisory Group first reported a position in ABBV in Q1 2024 and held it in 3 quarters. The position peaked at $579K in Q3 2024. 3,819 funds tracked by Wall St. Rank hold ABBV as of Q1 2025.

RIA Advisory Group reported no remaining AbbVie position as of Q1 2025 after selling out during the quarter.
RIA Advisory Group sold 3,077 AbbVie shares in Q1 2025, an estimated $547K.
RIA Advisory Group first reported a position in AbbVie in Q1 2024 and held it in 3 quarters.
RIA Advisory Group's AbbVie position peaked at $579K in Q3 2024.
3,819 funds tracked by Wall St. Rank held AbbVie as of Q1 2025.

Based on RIA Advisory Group's 13F filing for Q1 2025, filed 12 May 2025.